Go Deep
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,787 | -1.8 | 1.51 | 0.49 | 184.20 |
| Oct 2026 | 19,816 | -1.9 | 1.50 | 0.49 | 182.80 |
| Oct 2026 | 20,078 | -1.7 | 1.40 | 0.49 | 169.54 |
| Oct 2026 | 19,942 | -1.8 | 1.45 | 0.49 | 176.36 |
| Oct 2026 | 19,554 | -2.0 | 1.61 | 0.49 | 195.32 |
| Oct 2026 | 19,535 | -2.0 | 1.62 | 0.49 | 195.79 |
| Oct 2026 | 19,496 | -2.0 | 1.63 | 0.49 | 197.28 |
Fate Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 2,082,000.0 | 1,299,000.0 | 1,369,000.0 | 1,741,000.0 |
| Net Profit | -30,159,000.0 | -31,213,000.0 | -32,374,000.0 | -32,250,000.0 |
| EPS | -0.2 | -0.3 | -0.3 | -0.3 |
Fate Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 6,646,000.0 | 13,631,000.0 | 63,533,000.0 | 96,300,000.0 | — |
| Net Profit | -136,315,000.0 | -186,262,000.0 | -160,928,000.0 | -281,721,000.0 | — |
| EPS | -1.1 | -1.6 | -1.6 | -2.9 | — |
Fate Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 318,937,000.0 | 440,694,000.0 | 506,217,000.0 | 705,561,000.0 | — |
| Total Liabilities | 111,753,000.0 | 121,968,000.0 | 137,800,000.0 | 221,622,000.0 | — |
| Total Equity | 207,184,000.0 | 318,726,000.0 | 368,417,000.0 | 483,939,000.0 | — |
Owes vs Owns
Fate Therapeutics, Inc. owed $0.41 for every $1 it owned in Jun 2026, up from $0.31 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.41× | 0.35× | 0.28× | 0.27× | 0.31× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Fate Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 63.9%Fixed assets (tangible) 30.9%Other assets 4.5%
How it's funded — Dec 2025
Short-term debt 1.4%Long-term debt 23.0%Payables 0.8%Other liabilities 9.8%Shareholders' equity 65.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 203.7 | 279.1 | 315.2 | 436.2 |
| Receivables | 0.9 | 3.5 | 1.8 | 38.5 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 98.5 | 110.9 | 158.5 | 176.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 1.5 | 27.7 | 1.0 | 4.9 |
| Other assets | 14.4 | 19.5 | 29.7 | 49.8 |
| Liabilities & equity | ||||
| Short-term debt | 4.6 | 7.4 | 6.2 | 5.6 |
| Long-term debt | 73.3 | 77.8 | 97.4 | 103.7 |
| Payables | 2.7 | 9.4 | 4.7 | 8.3 |
| Other liabilities | 31.2 | 27.3 | 29.5 | 104.0 |
| Shareholders' equity | 207.2 | 318.7 | 368.4 | 483.9 |
| Net tangible assets | 207.2 | 318.7 | 368.4 | 483.9 |
Fate Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -106,084,000.0 | -122,874,000.0 | -132,263,000.0 | -248,208,000.0 | — |
| Investing Activities | 111,166,000.0 | 12,218,000.0 | 112,665,000.0 | 166,751,000.0 | — |
| Financing Activities | 5,490,000.0 | 99,892,000.0 | 85,000.0 | 9,207,000.0 | — |